2 . What two competing needs must the CSA and regulators attempt to balance? 3 . Which attribute of some drugs with legitimate therapeutic uses increases their likelihood of being abused? 6 . Uncomfortable or unpleasant side effects (aside from constipation) may potentially be reduced by which two approaches? 7 . What drug class has largely replaced barbiturates as treatment for anxiety and muscle spasms? 11 . Nonpharmacologic therapies for pain treatment 12 . Increased monitoring of patient response is essential during opioid dose initiation, upward titration, rotation, and addition of other central-nervous system depressants because 13 . For which of the following pain conditions are ER/LA opioids indicated? 14 . Which of the following is true of potential drug-drug interactions with opioids? 15 . Name one (1) way patients should be monitored for adherence to medical direction during long-term opioid therapy? 16 . Which of the following is one (1) indication for take-home naloxone with opioid prescription? 17 . Urine drug testing as a monitoring measure can tell the clinician which of the following: 19 . Which of the following is NOT a practice that clinicians can use to minimize diversion of controlled substances?